MNG658
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.445
- WNT_BETA_CATENIN_SIGNALING+0.340
- PEROXISOME+0.294
- CHOLESTEROL_HOMEOSTASIS+0.262
- NOTCH_SIGNALING+0.240
- TGF_BETA_SIGNALING+0.237
- BILE_ACID_METABOLISM+0.224
- MYC_TARGETS_V1+0.219
- OXIDATIVE_PHOSPHORYLATION+0.218
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.217
Top 10 suppressed
- E2F_TARGETS-0.372
- G2M_CHECKPOINT-0.337
- SPERMATOGENESIS-0.307
- ESTROGEN_RESPONSE_LATE-0.252
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- TNFA_SIGNALING_VIA_NFKB-0.223
- ANGIOGENESIS-0.179
- ESTROGEN_RESPONSE_EARLY-0.168
- MITOTIC_SPINDLE-0.159
- HYPOXIA-0.158
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5K6-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.662 |
| 2 | BS_9Q6Z6VJC | pilocytic astrocytoma | — | 0.639 |
| 3 | MNG659 | — | — | 0.633 |
| 4 | MNG1253 | — | — | 0.625 |
| 5 | 44B988F8-8B4B-4B7C-B91E-99C513F7E753 | — | — | 0.614 |
| 6 | 4DE8E786-DFE2-403E-948F-A4FA32177F59 | — | — | 0.612 |
| 7 | DRR168518 | — | — | 0.610 |
| 8 | SRR13311160 | — | — | 0.606 |
| 9 | MNG958 | — | — | 0.606 |
| 10 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.602 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.445 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PEROXISOME | 0.294 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.262 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.237 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.224 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.219 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.218 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.217 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.214 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.197 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.179 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.156 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.115 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.113 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.088 | Inavolisib | — uncovered |